Pudafensine not checked
Initiator Pharma · IP2015
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Vulvodynia
- Main trialPhase 2
- “The study (IP2015CS05) is a randomised, double-blind, placebo-controlled, 4-way cross-over trial studying the efficacy and safety of single dose administration of pudafensine in vulvodynia (provoked vestibulodynia) patients.”In the company’s words, NCT07391241 on ClinicalTrials.gov
- Other names
- IP2015 · Test drug
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Dec 2026 | A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia) | |
| Phase 1Unknown | 30 May 2022 | Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model | |
| Phase 1Unknown | 16 May 2023 | Bioavailability Study to Compare Liquid vs Two Solid Formulations of IP2015 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026